Metropolitan Life Insurance Company (MetLife)’s Cartesian Therapeutics RNAC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-236	Closed	-$7.5K	–	2382
2023 Q3	$7.5K	Buy	236 +21	+10%	+$702	﹤0.01%	2333
2023 Q2	$7.22K	Buy	+215	New	+$7.7K	﹤0.01%	2422
2022 Q1	–	Sell	-425	Closed	-$41.6K	–	2603
2021 Q4	$41.6K	Buy	425 +34	+9%	+$3.66K	﹤0.01%	2717
2021 Q3	$48.8K	Sell	391 -497	-56%	-$60K	﹤0.01%	2763
2021 Q2	$111K	Buy	+888	New	+$106K	﹤0.01%	2542
2020 Q3	–	Sell	-822	Closed	-$70K	–	2588
2020 Q2	$70K	Buy	+822	New	+$74.5K	﹤0.01%	2437
2018 Q4	–	Sell	-224	Closed	-$104K	–	2566
2018 Q3	$104K	Buy	+224	New	+$90K	﹤0.01%	2429
2017 Q4	–	Sell	-351	Closed	-$192K	–	2522
2017 Q3	$192K	Buy	+351	New	+$187K	﹤0.01%	2297

Other funds holding RNAC

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RNAC Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 236 shares — an estimated $7.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RNAC in Q3 2017 and held it in 8 quarters. The position peaked at $192K in Q3 2017. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 236 Cartesian Therapeutics shares in Q4 2023, an estimated $7.5K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Cartesian Therapeutics in Q3 2017 and held it in 8 quarters.
Metropolitan Life Insurance Company (MetLife)'s Cartesian Therapeutics position peaked at $192K in Q3 2017.
80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.